Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by Ghostofrljpon Jan 04, 2020 1:34am

258 Views

Post# 30517646

RE:RE:RE:Stock Sale Announced January 3, 2020

Its an agreement they finally released for action.

The box is shorted by canacord. The 14.8 could already be profit and the shares are purchased. Done deal by Canacord. They only needed to flip about 3 million shares in the US.

I do not expect this to put much weight on the stock considering the volume in the US.

All the company needs to do now is deliver.

But the spikes will be done until there is news imho.

Bullboard Posts

AtkinsRéalis supports Poland’s nuclear power endeavour